SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?


To: Rocketman who wrote (5911)11/11/1998 8:23:00 PM
From: Vector1  Read Replies (1) | Respond to of 9719
 
LOL
Rman, I am convinced that Bexxar will become the dominant therapuedic in the low grade NHL market. The management is highly motivated and very smart. I think they can earn close to $3 per share in 2002. The weakness is the pipeline. By and large this is a one drug company. Given they $100 m in cash I think they should forgo the marketing partner and do it themselves and then sell the company
V1